Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group

Basit Öğe Kaydı
dc.authorid0000-0002-1424-4706
dc.authorid0000-0001-9710-134X
dc.authorid0000-0001-5522-8342
dc.authorid0000-0001-5281-5955
dc.authorid0000-0001-8933-1081
dc.authorid0000-0001-5419-3221
dc.authorid0000-0001-9636-4113
dc.contributor.authorIsleyen, Emel
dc.contributor.authorAlhan, Nurcan
dc.contributor.authorTerzi Demirsoy, Esra
dc.contributor.authorGeduk, Ayfer
dc.contributor.authorAvci, Duygu Nurdan
dc.contributor.authorYeral, Mahmut
dc.contributor.authorFerhanoglu, Ahmet Burhan
dc.date.accessioned2026-01-24T12:26:35Z
dc.date.available2026-01-24T12:26:35Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: Classical Hodgkin lymphoma (cHL) demonstrates high survival rates with the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine); however, the use of bleomycin is associated with a significant risk of pulmonary toxicity. The Risk-Adapted Treatment of HL (RATHL) trial demonstrated that omitting bleomycin in patients with favorable interim Positron Emission Tomography (PET-CT) results did not adversely affect survival outcomes. In this study, we present real-world data from advanced-stage HL patients treated according to the RATHL protocol. Methods: This multicenter, retrospective study included newly diagnosed cHL patients with Ann Arbor stage IIB-IV disease or stage IIA disease with bulky disease or with involvement of three or more sites, enrolled from 29 centers across T & uuml;rkiye. The analysis focused on patients whose initial treatment was de-escalated from ABVD to AVD (bleomycin was omitted). Data were collected on demographic and clinical prognostic characteristics, interim PET-CT findings (evaluated using the Deauville score), progression-free survival (PFS) and overall survival (OS). Survival outcomes were assessed using Kaplan-Meier analysis. Results: A total of 379 patients were included, with a median age of 34 years (range: 18-78). Following interim PET-CT assessments (After 2 cycles of ABVD), Deauville scores were 1 in 39.8% of patients, 2 in 39.1%, and 3 in 21.1%. Based on these results, bleomycin was omitted immediately after interim PET-CT in 73.9% of patients, after one additional ABVD cycle in 12.1%, and after two additional cycles in 14%. The median follow-up duration was 28 months (range: 6-96). The 3-year PFS and OS rates were 86.0% and 96.1%, respectively. Patients with Deauville scores of 1-2 had a 3-year PFS rate of 87.6%, compared to 79.8% in those with a score of 3 (p = 0.087). Increased age, poor Eastern Cooperative Oncology Group Scale (ECOG) performance status, bulky disease, and higher International Prognostic Scores (IPS) were significantly associated with inferior OS (p < 0.05). There were no significant differences in OS among patients who received 2, 3, or 4 cycles of ABVD. However, among patients treated with 2 cycles of ABVD, both extranodal involvement (p = 0.039) and higher IPS (p = 0.002) were significantly associated with decreased PFS. Conclusions: Our findings demonstrate that PET-guided de-escalation of bleomycin after two cycles of ABVD is feasible, effective, and safe in real-world multicenter practice in T & uuml;rkiye. The survival outcomes are comparable to those reported in the RATHL study, reinforcing the role of interim PET-CT in guiding individualized therapy. However, patients with high IPS or extranodal involvement may require more tailored management strategies.
dc.identifier.doi10.3390/jcm14196813
dc.identifier.issn2077-0383
dc.identifier.issue19
dc.identifier.pmid41095893
dc.identifier.scopus2-s2.0-105018820626
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/jcm14196813
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4772
dc.identifier.volume14
dc.identifier.wosWOS:001594844900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofJournal of Clinical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectHodgkin's lymphoma
dc.subjectABVD
dc.subjectbleomycin omission
dc.subjectde-escalation
dc.subjectPET-CT
dc.titleReal-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu